Zacks Investment Research on MSN1d
Bayer's sNDA for Kerendia Label Expansion Gets FDA's Priority ReviewBayer AG BAYRY recently announced that the FDA had accepted its supplemental new drug application (sNDA) seeking approval for ...
Bayer's 2024 annual results showed a 2.2% sales decline, with only free cash flow improving significantly. Read why BAYZF ...
Bayer has won U.S. Food and Drug Administration priority review for its application seeking expanded approval of its kidney-disease drug Kerendia in certain people with heart failure.
The US Food and Drug Administration (FDA) accepted and granted Priority Review designation for Bayer’s (BAYN: DE) supplemental new drug application (sNDA) for a new indication for Kerendia (finerenone ...
Regulators are expected to make a decision in the third quarter of 2025 on Kerendia to treat patients with heart failure with ...
Berlin: Bayer has announced that the Company has received Priority Review designation from the U.S. Food and Drug ...
Healthcare companies rose as traders sought out sectors that are less vulnerable to swings in economic growth and inflation prospects.
Bayer has won U.S. Food and Drug Administration priority review for its application seeking expanded approval of its kidney-disease drug Kerendia in certain people with heart failure. Bayer on ...
Bayer has won U.S. Food and Drug Administration priority review for its application seeking expanded approval of its kidney-disease drug Kerendia in certain people with heart failure. Drug giant ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback